Weekly Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings as of May 17, 2018

May 17, 2018 - By Vernon Rice

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Corporate Logo
Big Money Sentiment increased to 3 in Q4 2017. It has change of 2.21, from 2017Q3’s 0.79. The ratio is positive due to Dicerna Pharmaceuticals, Inc. positioning: 6 sold and 5 reduced. 18 funds took holdings and 15 increased holdings. Investors holded 10.37 million in 2017Q3 but now own 29.10 million shares or 180.62% more.
Germany-based Deutsche Bank & Trust Ag has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Bridger Mngmt Lc, a New York-based fund reported 905,998 shs. Adage Prns Gp Ltd Llc owns 1.98M shs for 0.04% of their capital. Renaissance Tech Lc stated it has 560,300 shs. Cormorant Asset Management Limited Liability holds 3.66M shs. Royal State Bank Of Canada has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). California Employees Retirement owns 41,000 shs. Bancorp Of Mellon stated it has 19,579 shs. Moreover, Fmr Limited Liability Corp has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 1.71 million shs. Emerald Advisers Pa holds 29,504 shs. Vanguard owns 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 589,573 shs. The Pennsylvania-based Susquehanna Grp Llp has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Moreover, Endurant Capital Mgmt L P has 0.05% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Millennium Mgmt Ltd Llc has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Moreover, 683 Management Lc has 0.42% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 550,000 shs.

Dicerna Pharmaceuticals, Inc. registered $1.57 million net activity with 1 buy and 4 insider sales since December 18, 2017. Bain Capital Life Sciences Investors – LLC bought 285,000 shs worth $2.00M. On Wednesday, May 9 Weissman James B also sold $150,000 worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA).

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings Coverage

A total of 8 analysts rate Dicerna Pharmaceuticals (NASDAQ:DRNA) as follows: 4 “Buy”, 4 “Hold” and 0 “Sell”. Тherefore 50% are bullish. (NASDAQ:DRNA) has 8 ratings reports on May 17, 2018 according to StockzIntelligence. The company rating was initiated by SunTrust on Monday, February 5. On Friday, March 23 the company was downgraded by H.C. Wainwright. On Tuesday, March 27 FBR Capital initiated the shares of DRNA in report with “Hold” rating. The stock rating was maintained by Stifel Nicolaus with “Buy” on Friday, March 9. On Wednesday, April 11 the stock has “Buy” rating by Cowen & Co. The company rating was initiated by Chardan Capital Markets on Friday, March 9. Listed here are Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) PTs and latest ratings.

11/04/2018 Broker: Cowen & Co Rating: Buy Initiate
28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $10 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $10.0000 Initiate
23/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral Old Target: $7 Downgrade
09/03/2018 Broker: Chardan Capital Markets Rating: Hold Initiate
09/03/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $10 New Target: $17 Maintain
05/02/2018 Broker: SunTrust Rating: Buy New Target: $13.0 Initiate
16/01/2018 Broker: Evercore Rating: Outperform New Target: $14 Initiates Coverage On

The stock decreased 0.04% or $0.01 during the last trading session, reaching $13.76.Dicerna Pharmaceuticals, Inc. has volume of 29,107 shares. Since May 17, 2017 DRNA has risen 274.53% and is uptrending. DRNA outperformed by 262.98% the S&P 500.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally.The firm is valued at $712.73 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases.Last it reported negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

More recent Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news were brought out by Streetinsider.com, Businesswire.com and Benzinga.com. The first one has “Dicerna Pharmaceuticals (DRNA) PT Raised to $18 at Stifel” as a title and was brought out on May 15, 2018. The next is “Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update” on May 14, 2018. And last was brought out on May 14, 2018, called “Earnings Scheduled For May 14, 2018”.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.